European Commission approves CAPRELSA® (vandetanib) for patients with advanced medullary thyroid cancer
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
List view / Grid view
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
20 February 2012 | By Roche
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer...
20 February 2012 | By Daiichi Sankyo
The European Commission has approved Zelboraf® (vemurafenib)...
18 February 2012 | By Bristol-Myers Squibb
Three new grants awarded...
17 February 2012 | By Gilead Sciences
Viral relapse seen post treatment with GS-7977 plus ribavirin...
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
17 February 2012 | By GlaxoSmithKline
The EMA's CHMP has issued a positive opinion recommending marketing authorisation for Nimenrix® (MenACWY-TT)...
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
17 February 2012 | By Abbott
Positive opinion based on supporting data from two Phase III clinical studies...
17 February 2012 | By Pfizer
The framework agreement builds upon the MOU, and is an important milestone in the formation of a joint venture between the two companies...
16 February 2012 | By GlaxoSmithKline
GlaxoSmithKline has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib)...
Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Stuart Grant has been appointed Patheon's Executive Vice President, Chief Financial Officer. Mr. Grant comes to Patheon following an accomplished career with increasing levels of responsibility in finance for several…
15 February 2012 | By Pfizer
A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)...
15 February 2012 | By Amgen
Amgen and Micromet entered into a Merger Agreement...
15 February 2012 | By Merck
New Brazilian joint venture to combine local and global commercial expertise...